Knowledge of the exact dose and rate at which an antitumor agent is delivered to its target site is postulated to be crucial to proper patient management. It is now possible to obtain such information using noninvasive 19 F-NMRS (nuclear magnetic resonance spectroscopy) following the administration
The use of transgenic mice in pharmacokinetic and pharmacodynamic studies
β Scribed by William F. Elmquist; Donald W. Miller
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 242 KB
- Volume
- 90
- Category
- Article
- ISSN
- 0022-3549
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Rat heme oxygenase (HO) activity was used as a specific (among forms of arsenic) and sensitive biomarker of effect for orally administered sodium arsenite in rats. Time course studies showed that HO was induced in rat liver from 2 to 48 h in both rat liver and kidney. Hepatic and renal inorganic ars
Gazing into a crystal ball at the behest of the Environmental Mutagen Society, I see three paths, all leading to Investigation of Spontaneous Mutation more sophisticated questions about heritable mutations, somatic mutations, cancer, and other diseases. Those fol-Studies with transgenic animals have
Mivacurium, a non-depolarizing neuromuscular blocking agent, consists of three isomers; trans-trans (57%), cis-trans (36%) and cis-cis (7%). The purpose of this study was to characterize the pharmacokinetics and pharmacodynamics of mivacurium after various inputs. Four beagle dogs weighing between 7
The eects of pretreatment with the enzyme inducers phenobarbital (PB) and 3methylcholanthrene (3-MC) and the enzyme inhibitor chloramphenicol (CM) on the pharmacokinetic and pharmacodynamic parameters of azosemide were examined after intravenous (IV) administration of azosemide, 10 mg kg 71 , to rat
Ebastine (EBS), a novel nonsedative antiallergic agent, is similar to terfenadine in its chemical structure. However, clinical arrhythmogenicity of EBS remains controversial. In this study, we evaluated the possible arrhythmogenic potency of EBS as assessed by QT prolongation from a pharmacokinetic-